ADDvise Group’s CEO divests shares - remains a committed and long-term shareholder

22-08-2023   Regulatory press release

Rikard Akhtarzand, CEO of ADDvise Group AB (publ) (“ADDvise” or the “Company”), has informed the Company that he has sold 2,500,000 Class B shares in ADDvise, representing approximately 1.3% of total outstanding shares and 18.1% of his total shareholding in the Company, and that he has entered a 180-day lock-up agreement for his remaining shares. The shares were sold in a block trade to Swedish and international investors, including the Company’s Chairman Staffan Torstensson and largest owner Per Åhlgren. Following the transaction, Rikard Akhtarzand holds 2,620,416 Class A shares and 8 658 493 Class B shares.

Rikard Akhtarzand comments: “The divestment is solely made for private financial reasons, and I do not intend to sell additional shares and have therefore agreed to enter a lock-up agreement of 180 days on my remaining shares to emphasize this. The proceeds from the share sale will be used to finance costs related to a divorce. I have great faith in the future of ADDvise Group and I look forward to continuing to lead the company going forward.”
 

Important information

This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on August 22, 2023 at 15:40 CEST.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business units: Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business—both geographically and product-wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market, and Mangold Fondkommission AB, +46 (0)8-503 015 50, CA@mangold.se, is the company’s certified adviser. Further information is available at www.addvisegroup.com.

 

Latest press releases

Interim report 2025, January 1–March 31

Regulatory

In the first quarter of 2025, net revenue increased organically with continued good profitability, which shows stable demand in medical technology and laboratory solutions. Cash flow from operating activities was strong, driven by improved working capital while EBITA, the company’s new main profit measure, decreased compared to the same quarter last year. Through increased operational…

Invitation to presentation of interim report January 1 – March 31, 2025

Non-regulatory

ADDvise Group publishes its interim report January 1 – March 31, 2025 on Friday, May 9, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and Interim CFO, Johan Irwe, will present the report. Webcast If you wish…

Notice to the annual general meeting of ADDvise Group AB (publ)

Regulatory

ADDvise Group AB (publ), reg. no. 556363–2115, hereby convenes the annual general meeting on 12 May 2025 at 10:00 CEST at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09.30 CEST. NOTIFICATION Shareholders wishing to attend the annual general meeting must: i)          be registered in the share register kept by Euroclear Sweden AB on the…

ADDvise raises approximately SEK 457 million in the rights issue

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL,…